iFR Guided Multi-vessel Revascularization During Percutaneous Coronary Intervention for Acute Myocardial Infarction
- Conditions
- Acute Myocardial InfarctionMulti Vessel Coronary Artery Disease
- Interventions
- Diagnostic Test: iFRDiagnostic Test: CMR
- Registration Number
- NCT03298659
- Lead Sponsor
- Radboud University Medical Center
- Brief Summary
In patients with acute ST-elevation myocardial infarction (STEMI), 40-60% have multi-vessel disease with an increased cardiovascular morbidity and mortality. Although it is not recommended to revascularize noninfarct lesions during the acute intervention, recent investigations suggest the opposite and show improved outcome after direct revascularization of noninfarct lesions. It is undesirable to risk procedure-related complications by treating noninfarct lesions without impaired flow. It is currently unknown whether pressure guided revascularization of noninfarct lesions in the acute phase improves outcome compared to the current guidelines.
The iMODERN trial aims to compare an iFR-guided intervention of noninfarct lesions during the acute intervention with a deferred stress perfusion CMR-guided strategy during the outpatient follow-up, to determine the optimal therapeutic approach for STEMI patients with multivessel lesions.
- Detailed Description
Study design:
The study is a prospective, randomized controlled, multicentre study.
Study population:
The research population will be recruited from the general patient population presenting with an acute STEMI. Patients treated with successful primary PCI and one or more additional significant coronary lesions in another coronary artery will be enrolled in the study. A total of 1,146 consecutive patients will be included.
Intervention:
The patients will be randomized 1:1, to (A) an active treatment arm with complete, iFR-guided revascularization of every noninfarct coronary lesion \>50% and iFR ≤0.89; (B) a deferred treatment arm, in which patients will undergo an adenosine stress perfusion CMR scan within 6 weeks after STEMI, with revascularization of the noninfarct coronary lesions with associated perfusion defects.
Main study parameters/endpoints:
The primary end point consists of a combined outcome, including all-cause death, recurrent MI and hospitalization for heart failure at 3 years follow-up.
Duration:
Anticipated recruitment is 2 years. Follow-up will be performed at 6 months, 12 months, 3 years and 5 years.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1146
- Clinical presentation of STEMI and successful primary PCI within 12 hours from onset of symptoms.
- One or more other, noninfarct coronary artery lesions of >50% stenosis and feasible to be revascularized (i.e. minimal diameter 2mm).
- History of myocardial infarction.
- Hemodynamic instability, respiratory failure, Kilips class ≥III.
- Known GFR<30 ml/min.
- Known contra-indications for stress CMR (e.g.: severe claustrophobia, metal implants, severe renal failure, severe astma).
- Refusal or inability to provide informed consent.
- Life expectancy due to noncardiovascular co-morbidity of less than 12 months.
- Chronic total occlusion.
- Left main stem stenosis (>50%).
- Residual noninfarct lesion in infarct coronary artery.
- Complex (e.g. bifurcation) noninfarct target lesions.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Active iFR-guided revascularization iFR Decision to treat the nonculprit coronary stenosis if there is a significant pressure drop over the stenosis, as measured by intracoronary iFR assessment Deferred CMR-guided revascularization CMR Decision to treat the nonculprit coronary stenosis if perfusion defect visible in corresponding coronary territory as visualized on stress perfusion CMR imaging
- Primary Outcome Measures
Name Time Method Composite end point of Major Adverse Cardiac Events 3 years All-cause death, recurrent myocardial infarction and hospitalization for heart failure
- Secondary Outcome Measures
Name Time Method All cause mortality 6 and 12 months, 3 and 5 years All cause mortality at 6 and 12 months, 3 and 5 years
Cardiovascular mortality 6 and 12 months, 3 and 5 years Cardiovascular mortality at 6 and 12 months, 3 and 5 years
Revascularization 6 and 12 months, 3 and 5 years Any revascularization at 6 and 12 months, 3 and 5 years
Target lesion failure 6 and 12 months, 3 and 5 years Failure and/or revascularization by percutaneous or surgical methods of the target lesion
Stent thrombosis 6 and 12 months, 3 and 5 years Stent thrombosis at 6 and 12 months, 3 and 5 years
Myocardial infarction 6 and 12 months, 3 and 5 years Myocardial infarction at 6 and 12 months, 3 and 5 years
Unstable angina 6 and 12 months, 3 and 5 years Unstable angina including ECG-changes at 6 and 12 months, 3 and 5 years
Coronary angiography 6 and 12 months, 3 and 5 years Coronary angiography at 6 and 12 months, 3 and 5 years
Cerebral events 6 and 12 months, 3 and 5 years Stroke and transient ischemic attack
Major bleeding 6 months Haemorrhagic complications
Cost effectiveness analysis 6 and 12 months, 3 and 5 years Costs related to complete, iFR-guided revascularization versus CMR-guided treatment, including cost utility analysisfrom a societal perspective with the costs per prevented cardiac eventand the costs per QALY as the respective primary health economic outcomes (using a quality of life questionnaire and a health care resource use questionnaire)
Quality of life 6 and 12 months, 3 and 5 years Quality of life questionnaires, i.e. SAQ, EQ-5D-5L and Minnesota heart failure questionnaire, at 6 and 12 months, 3 and 5 years
Trial Locations
- Locations (1)
Radboudumc
🇳🇱Nijmegen, Netherlands